Modeling disease in the mouse: Lessons from DNA damage response and cell cycle control genes

The advent of gene targeting has allowed the dissection of many essential cellular pathways, including those involved in cell cycle regulation, signal transduction, and development. However, it is becoming increasingly clear that the simple gene deletion strategy may not be sufficient for the modeling of many cancer syndromes. In this Prospect article, we will discuss the strengths and weaknesses of mouse models, how they have advanced from gene deletions to truncations, point mutations, and conditional mouse models in which expression or loss of the gene of interest is controlled either temporally or spatially. We will also consider future directions for the use of mouse models in cancer. The vastness of the field necessitates focusing on a few specific examples with the unfortunate exclusion of many excellent studies from our discussion. As such, we focus on a few specific models of human cancer syndromes, however many of the themes discussed here are applicable to other systems of genetic manipulation and may be applied across fields. J. Cell. Biochem. © 2005 Wiley‐Liss, Inc.

[1]  A. Berns,et al.  p107 is a suppressor of retinoblastoma development in pRb-deficient mice. , 1998, Genes & development.

[2]  Nijmegen breakage syndrome , 2000, Archives of disease in childhood.

[3]  Harry Scherthan,et al.  Atm Inactivation Results in Aberrant Telomere Clustering during Meiotic Prophase , 1999, Molecular and Cellular Biology.

[4]  F. Alt,et al.  Checkpoint failure and chromosomal instability without lymphomagenesis in Mre11(ATLD1/ATLD1) mice. , 2003, Molecular cell.

[5]  Angelika Amon,et al.  Meiosis: cell-cycle controls shuffle and deal , 2004, Nature Reviews Molecular Cell Biology.

[6]  M. Kapoor,et al.  High metastatic potential in mice inheriting a targeted p53 missense mutation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  L. Siracusa,et al.  Identification of the modifier of Min 2 (Mom2) locus, a new mutation that influences Apc-induced intestinal neoplasia. , 2002, Genome research.

[8]  D. Easton,et al.  Inherited susceptibility to breast cancer. , 1993, Cancer surveys.

[9]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[10]  F. McCormick,et al.  The RB and p53 pathways in cancer. , 2002, Cancer cell.

[11]  Il-Jin Kim,et al.  [Hereditary colorectal cancer]. , 2005, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.

[12]  J. Petrini,et al.  The cellular response to DNA double-strand breaks: defining the sensors and mediators. , 2003, Trends in cell biology.

[13]  S. Seal,et al.  Heterozygosity for mutations in the ataxia telangiectasia gene is not a major cause of radiotherapy complications in breast cancer patients. , 1998, British Journal of Cancer.

[14]  A. de la Chapelle,et al.  Genetic susceptibility to non-polyposis colorectal cancer , 1999, Journal of medical genetics.

[15]  D. Purdie,et al.  Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer , 2002, Nature Genetics.

[16]  K. Khanna Cancer risk and the ATM gene: a continuing debate. , 2000, Journal of the National Cancer Institute.

[17]  A. Berns,et al.  Developmental rescue of an embryonic‐lethal mutation in the retinoblastoma gene in chimeric mice. , 1994, The EMBO journal.

[18]  K. Isselbacher,et al.  Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.

[19]  A. Bradley,et al.  Disruption of mRad50 causes embryonic stem cell lethality, abnormal embryonic development, and sensitivity to ionizing radiation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Camerini-Otero,et al.  SPO11 is required for sex-body formation, and Spo11 heterozygosity rescues the prophase arrest of Atm-/- spermatocytes , 2005, Journal of Cell Science.

[21]  Lynda Chin,et al.  Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice , 2000, Nature.

[22]  E. Harlow,et al.  The retinoblastoma tumour suppressor in development and cancer , 2002, Nature Reviews Cancer.

[23]  O. Kallioniemi,et al.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. , 2002, American journal of human genetics.

[24]  P. Rowley Inherited susceptibility to colorectal cancer. , 2005, Annual review of medicine.

[25]  Lino Tessarollo,et al.  Targeted disruption of the Nijmegen breakage syndrome gene NBS1 leads to early embryonic lethality in mice , 2001, Current Biology.

[26]  Asad Umar,et al.  Meiotic Pachytene Arrest in MLH1-Deficient Mice , 1996, Cell.

[27]  E. Berns,et al.  Is TP53 dysfunction required for BRCA1-associated carcinogenesis? , 1999, Molecular and Cellular Endocrinology.

[28]  M. Nussenzweig,et al.  Genomic instability, endoreduplication, and diminished Ig class-switch recombination in B cells lacking Nbs1. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Lavin,et al.  Testing for mutations of the ataxia telangiectasia gene in radiosensitive breast cancer patients. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[30]  G. Kay,et al.  Atm Knockin Mice Harboring an In-frame Deletion Corresponding to the Human ATM 7636 del 9 Common Mutation Exhibit a Variant Phenotype 1 , 2001 .

[31]  Arthur M Buchberg,et al.  The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin -induced intestinal neoplasia , 1995, Cell.

[32]  J. Carlin,et al.  Familial aggregation of a disease consequent upon correlation between relatives in a risk factor measured on a continuous scale. , 1992, American journal of epidemiology.

[33]  E. Appella,et al.  Chk2‐deficient mice exhibit radioresistance and defective p53‐mediated transcription , 2002, The EMBO journal.

[34]  Christopher J Bakkenist,et al.  Initiating Cellular Stress Responses , 2004, Cell.

[35]  D. Harrison,et al.  Effects of heterozygosity for the Rb-1t19neo allele in the mouse. , 1995, Oncogene.

[36]  C. Deng,et al.  Impaired meiotic DNA-damage repair and lack of crossing-over during spermatogenesis in BRCA1 full-length isoform deficient mice , 2003, Development.

[37]  R. Houlston,et al.  Explaining variation in familial adenomatous polyposis: relationship between genotype and phenotype and evidence for modifier genes , 2002, Gut.

[38]  K. Sperling,et al.  Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks. , 2004, DNA repair.

[39]  T. Jacks,et al.  Cell type-specific effects of Rb deletion in the murine retina. , 2004, Genes & development.

[40]  M. Skolnick,et al.  The incidence and gene frequency of ataxia-telangiectasia in the United States. , 1986, American journal of human genetics.

[41]  Jiri Bartek,et al.  Cell-cycle checkpoints and cancer , 2004, Nature.

[42]  P. Byrd,et al.  Ataxia-telangiectasia-like disorder (ATLD)-its clinical presentation and molecular basis. , 2004, DNA repair.

[43]  L. Siracusa,et al.  Exclusion of Madh2, Madh4, and Madh7 as candidates for the modifier of Min 2 (Mom2) locus , 2003, Mammalian Genome.

[44]  V. Godfrey,et al.  CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. , 1998, Genes & development.

[45]  T. Stankovic,et al.  Absence of mutations in the ATM gene in breast cancer patients with severe responses to radiotherapy. , 1997, British Journal of Cancer.

[46]  P. Mckinnon ATM and ataxia telangiectasia , 2004, EMBO reports.

[47]  J. German Bloom's syndrome. I. Genetical and clinical observations in the first twenty-seven patients. , 1969, American journal of human genetics.

[48]  William F. Morgan,et al.  A Murine Model of Nijmegen Breakage Syndrome , 2002, Current Biology.

[49]  T. Dörk,et al.  Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[50]  P. Jeggo,et al.  Chk2 Is a Tumor Suppressor That Regulates Apoptosis in both an Ataxia Telangiectasia Mutated (ATM)-Dependent and an ATM-Independent Manner , 2002, Molecular and Cellular Biology.

[51]  Z. Herceg,et al.  An essential function for NBS1 in the prevention of ataxia and cerebellar defects , 2005, Nature Medicine.

[52]  S. Keeney,et al.  Mechanism and control of meiotic recombination initiation. , 2001, Current topics in developmental biology.

[53]  L. Donehower,et al.  Genetic background alters the spectrum of tumors that develop in p53‐deficient mice , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[54]  M. Newton,et al.  The intestinal epithelium and its neoplasms: genetic, cellular and tissue interactions. , 1998, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[55]  T. Lange Protection of mammalian telomeres , 2002, Oncogene.

[56]  N. Kleckner,et al.  Meiotic chromosomes: integrating structure and function. , 1999, Annual review of genetics.

[57]  A. Tward,et al.  Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. , 1999, Molecular genetics and metabolism.

[58]  W. Bodmer,et al.  Variants at the secretory phospholipase A2 (PLA2G2A) locus: analysis of associations with familial adenomatous polyposis and sporadic colorectal tumours , 1996, Annals of human genetics.

[59]  T. Ried,et al.  Atm deficiency results in severe meiotic disruption as early as leptonema of prophase I. , 1998, Development.

[60]  Nobuyuki Shishido,et al.  Mice Lacking p27 Kip1 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors , 1996, Cell.

[61]  Andreas Radbruch,et al.  Nibrin functions in Ig class-switch recombination. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[62]  S. Matsuura [Nijmegen breakage syndrome]. , 2001, Ryoikibetsu shokogun shirizu.

[63]  K. Manova,et al.  Role of Nbs1 in the activation of the Atm kinase revealed in humanized mouse models , 2005, Nature Cell Biology.

[64]  Michel C. Nussenzweig,et al.  Genomic Instability in Mice Lacking Histone H2AX , 2002, Science.

[65]  F. Kittrell,et al.  Radiation induces genomic instability and mammary ductal dysplasia in Atm heterozygous mice , 2001, Oncogene.

[66]  C. Deng,et al.  Partial rescue of the prophase I defects of Atm-deficient mice by p53 and p21 null alleles , 1997, Nature Genetics.

[67]  S. Hodgson,et al.  Rapid and efficient ATM mutation detection by fluorescent chemical cleavage of mismatch: identification of four novel mutations , 1999, European Journal of Human Genetics.

[68]  K. Isselbacher,et al.  Heterozygous ATM mutations do not contribute to early onset of breast cancer , 1997, Nature Genetics.

[69]  K. Kinzler,et al.  Analysis of mismatch repair genes in hereditary non–polyposis colorectal cancer patients , 1996, Nature Medicine.

[70]  R. Kucherlapati,et al.  Mutation in the Mismatch Repair Gene Msh6 Causes Cancer Susceptibility , 1997, Cell.

[71]  R. Bronson,et al.  A dynamic switch in Rb+/− mediated neuroendocrine tumorigenesis , 2004, Oncogene.

[72]  E. Fearon Human cancer syndromes: clues to the origin and nature of cancer. , 1997, Science.

[73]  J. Hall,et al.  The ATM gene and breast cancer: is it really a risk factor? , 2000, Mutation research.

[74]  A. Schäffer,et al.  Atm haploinsufficiency results in increased sensitivity to sublethal doses of ionizing radiation in mice , 1999, Nature Genetics.

[75]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[76]  R. Hawley,et al.  The genetics and molecular biology of the synaptonemal complex. , 2004, Annual review of cell and developmental biology.

[77]  E. Boder Ataxia-telangiectasia: some historic, clinical and pathologic observations. , 1975, Birth defects original article series.

[78]  J. Petrini,et al.  The Mre11 complex and the metabolism of chromosome breaks: the importance of communicating and holding things together. , 2004, DNA repair.

[79]  K. Chrzanowska,et al.  Nijmegen breakage syndrome. , 1996, Journal of medical genetics.

[80]  Matthias Mann,et al.  Cell-cycle-regulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres , 2000, Nature Genetics.

[81]  F. Kittrell,et al.  Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. , 2000, The American journal of pathology.

[82]  G. Kay,et al.  Atm knock-in mice harboring an in-frame deletion corresponding to the human ATM 7636del9 common mutation exhibit a variant phenotype. , 2001, Cancer research.

[83]  J. Groden,et al.  Bloom's syndrome , 1992, Human Genetics.

[84]  T. Pandita,et al.  The role of the DNA double-strand break response network in meiosis. , 2004, DNA repair.

[85]  R. Bronson,et al.  Targeted disruption of NBS1 reveals its roles in mouse development and DNA repair , 2002, The EMBO journal.

[86]  J. Varley Germline TP53 mutations and Li‐Fraumeni syndrome , 2003, Human mutation.

[87]  F. Alt,et al.  Functional Interaction of H2AX, NBS1, and p53 in ATM-Dependent DNA Damage Responses and Tumor Suppression , 2005, Molecular and Cellular Biology.

[88]  D. Baltimore,et al.  Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. , 1996, Genes & development.

[89]  J. Shay,et al.  Telomere dynamics in cancer progression and prevention: fundamental differences in human and mouse telomere biology , 2000, Nature Medicine.

[90]  G. Roeder Meiotic chromosomes: it takes two to tango. , 1997, Genes & development.

[91]  Francis Collins,et al.  Atm-Deficient Mice: A Paradigm of Ataxia Telangiectasia , 1996, Cell.

[92]  M. Swift,et al.  Breast and other cancers in families with ataxia-telangiectasia. , 1987, The New England journal of medicine.

[93]  J. Tytell,et al.  Germ-line msh6 mutations in colorectal cancer families. , 1999, Cancer research.